Overview of dosimetry for systemic targeted radionuclide therapy (STaRT)

International Journal of Radiation Oncology Biology Physics

Volumn 66, Issue SUPPL. 2, 2006, Pages

  Wessels, Barry W ^a   Syh, Joseph H ^a   Meredith, Ruby F ^b  

^a CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Internal dosimetry; Radioimmunotherapy; Radionuclide therapy

Indexed keywords

DISEASE CONTROL; DOSIMETRY; IMMUNOLOGY; RADIOISOTOPES; TISSUE; TUMORS;

INTERNAL DOSIMETRY; RADIOIMMUNOTHERAPY; RADIONUCLIDE THERAPY;

RADIOMETRY;

IBRITUMOMAB TIUXETAN; INDIUM 111; RADIOPHARMACEUTICAL AGENT; TOSITUMOMAB I 131; TRACER; YTTRIUM 90;

ACCURACY; ARTICLE; BLOOD TOXICITY; BONE MARROW; BONE MARROW SUPPRESSION; CANCER CONTROL; CLINICAL TRIAL; COMPUTER ASSISTED RADIOGRAPHY; COMPUTER ASSISTED THERAPY; CORRELATION ANALYSIS; DATA BASE; DOSE CALCULATION; DOSE RESPONSE; DOSIMETRY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EXCRETION; HUMAN; IMAGING SYSTEM; INFORMATION PROCESSING; NONHUMAN; ORGAN; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION ABSORPTION; RADIATION DOSE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION; RADIATION RESPONSE; RADIATION SAFETY; RADIOIMMUNOTHERAPY; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STANDARDIZATION; SYSTEMIC TARGETED RADIONUCLIDE THERAPY; TUMOR;

BRAIN; DOSE-RESPONSE RELATIONSHIP, RADIATION; ELECTRONS; HUMANS; RADIOIMMUNOTHERAPY; RADIOMETRY; RADIOPHARMACEUTICALS; RADIOTHERAPY DOSAGE; RADIOTHERAPY PLANNING, COMPUTER-ASSISTED; RELATIVE BIOLOGICAL EFFECTIVENESS; TISSUE DISTRIBUTION;

EID: 33748470909     PISSN: 03603016     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijrobp.2006.05.069     Document Type: Article

References (49)

1. Loevinger R., Budinger T.F., and Watson E.E. MIRD primer for absorbed dose calculations, revised (1991), The Society of Nuclear Medicine, New York
2. Howell R.W., Wessels B.W., and Loevinger R. The MIRD prospective 1999. J Nucl Med 40 (1999) 3S-10S
3. Loeevinger R., and Berman M. A schema for absorbed-dose calculations for biologically-distributed radionuclides. J Nucl Med Suppl.1 (1968) 9-14 Feb
4. Buchsbaum D.J., Langmuir V.K., and Wessels B.W. Experimental radioimmunotherapy. Med Phys 20 (1993) 551-567
5. Siegel J.A., Thomas S.R., Stubbs J.B., et al. MIRD Pamphlet No. 16: Techniques for quantitative radiopharmaceutical biodistribution data acquisition and analysis for use in human radiation dose estimates. J Nucl Med 40 (1999) 37S-61S
6. Yorke E.D., Williams L.E., Demidecki A.J., et al. Multicellular dosimetry for beta-emitting radionuclides: Autoradiography, thermoluminescent dosimetry, and three-dimensional dose calculations. Med Phys 20 (1993) 543-550
7. Wessels B.W., and Meares C.F. Physical and chemical properties of radionuclide therapy. Semin Radiat Oncol 10 (2000) 115-122
8. Leichner P.K., Koral K.F., Jaszczak R.J., et al. An overview of imaging techniques and physical aspects of treatment planning in radioimmunotherapy. Med Phys 20 (1993) 569-577
9. Snyder W.S., Ford M.R., Warner G.G., et al. 'S' absorbed dose per unit cumulated activity for selected radionuclides and organs (1975), The Society of Nuclear Medicine, New York MIRD Pamphlet No. 11, revised.
10. Fisher D. Dosimetry overview for radionuclide therapy. Semin Radiat Oncol 10 (2000) 123-132
11. Macey D.J., Williams L.E., Breitz H.B., et al. AAPM report no. 71, A primer for radioimmunotherapy and radionuclide therapy (2001), Medical Physics Publishing, Madison, WI
12. Bolch W.E., Bouchet L.G., Robertson J.S., et al. MIRD Pamphlet No. 17: The dosimetry of nonuniform activity distributions-radionuclide S values at the voxel level. J Nucl Med 40 (1999) 11S-36S
13. Bouchet L.G., Bolch W.E., Blanco H.P., et al. MIRD pamphlet No. 19: absorbed fractions and radionuclide S values for six age-dependent multiregion models of the kidney. J Nucl Med 44 (2003) 1113-1147
14. Stabin M.G. Developments in the internal dosimetry of radiopharmaceuticals. Radiat Prot Dosim 105 (2003) 575-580
15. Sgouros G. Dosimetry of internal emitters. J Nucl Med 46 Suppl (2005) 18S-27S
16. Stabin M.G. MIRDOSE. Personal computer software for internal dose assessment in nuclear medicine. J Nucl Med 37 (1996) 538-546
17. Johnson T.K. MABDOS: A generalized program for internal radionuclide dosimetry. Comp Meth Progr Biomed 27 (1998) 159-167
18. Johnson T.K., McClure D., and McCourt S. MABDOSE. I: Characterization of a general purpose dose estimation code. Med Phys 26 (1999) 1389-1395
19. Johnson T.K., McClure D., and McCourt S. MABDOSE. II: Validation of a general purpose dose estimation code. Med Phys 26 (1999) 1396-1403
20. Sgouros G., Barest G., Thekkumthala J., et al. Treatment planning for internal radionuclide therapy: Three-dimensional dosimetry for nonuniformly distributed radionuclides. J Nucl Med 31 (1990) 1884-1891
21. Sgouros G., Squeri S., Ballangrud A.M., et al. Patient specific, 3-dimensional dosimetry in non-Hodgkin's lymphoma patients treated with 131-I-anti-B1 antibody: Assessment of tumor dose-response. J Nucl Med 44 (2003) 260-268
22. Erwin W.D., Groch M.W., Macey D.J., et al. A radioimmunoimaging and MIRD dosimetry treatment planning program for radioimmunotherapy. Nucl Med Biol 23 (1996) 525-532
23. Erdi A.K., Erdi Y.E., Yorke E.D., et al. Treatment planning for radio-immunotherapy. Phys Med Biol 41 (1996) 2009-2026
24. Erdi A.K., Yorke E.D., Loew M.H., et al. Use of the fast Hartley transform for three-dimensional dose calculation in radionuclide therapy. Med Phys 25 (1998) 2226-2233
25. Ljungberg M., Frey E., Sjogreen K., et al. 3-dimensional absorbed dose calculation method based on quantitative SPECT for radionuclide therapy: Evaluation for 131-I using Monte Carlo simulation. J Nucl Med 43 (2002) 1101-1109
26. New internal radiation dose and modeling software; FDA approves commercial MIRDOSE successor. J Nucl Med 45 (2004) 26N-28N
27. Eary J.F., Press O.W., Badger C.C., et al. Imaging and treatment of B-cell lymphoma. J Nucl Med 31 (1990) 1257-1268
28. Murray J.L., Macey D.J., Kasi L.P., et al. Phase II radioimmunotherapy trial with 131I-CC49 in colorectal cancer. Cancer 73 (1994) 1057-1066
29. Meredith R.F., Khazaeli M.B., Plott G., et al. Comparison of diagnostic and therapeutic doses of I-131-LYM-1 in patients with non-Hodgkin's lymphoma. Antibody Immunoconj Radiopharmacol 6 (1993) 1-11
30. Clarke K.G., Odom-Maryon T.L., Williams L.E., et al. Intrapatient consistency of imaging biodistributions and their application to predicting therapeutic doses in a phase I clinical study of 90Y-based radioimmunotherapy. Med Phys 26 (1999) 799-809
31. Siegel J.A., Wessels B.W., Watson E.E., et al. Bone marrow dosimetry and toxicity for radioimmunotherapy. Antibody Immunconj Radiopharmacol 3 (1990) 213-233
32. Sgouros G. Bone marrow dosimetry for radioimmunotherapy: Theoretical considerations. J Nucl Med 34 (1993) 689-694
33. Sgouros G., Stabin M., Erdi Y., et al. Red marrow dosimetry for radiolabeled antibodies that bind to marrow, bone, or blood components. Med Phys 27 (2000) 2150-2164
34. Wessels B.W., Bolch W.E., Bouchet L.G., et al. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: A multiinstitutional comparison. J Nucl Med 45 (2004) 1725-1733
35. Macey D.J., DeNardo S.J., DeNardo G.L., et al. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy. Clin Nucl Med 20 (1995) 117-125
36. Shen S., Meredith R.F., Duan J., et al. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy. J Nucl Med 43 (2002) 1245-1253
37. Clairand I., Bouchet L.G., Ricard M., et al. Improvement of internal dose calculations using mathematical models of different adult heights. Phys Med Biol 45 (2000) 2771-2785
38. Wiseman G.A., Kornmehl E., Leigh B., et al. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med 44 (2003) 465-474
39. Zelenetz A.D. A clinical and scientific overview of tositumomab and iodine I 131 tositumomab. Semin Oncol 30 Suppl. 4 (2003) 22-30
40. Knox S.J., and Meredith R.F. Clinical radioimmunotherapy. Semin Radiat Oncol 10 (2000) 73-93
41. Bouchet L.G., Bolch W.E., Weber D.A., et al. A revised dosimetric model of the adult head and brain. J Nucl Med 37 (1996) 1226-1236
42. Wessels B. Summary and perspectives on kidney dose-response to radionuclide therapy. Cancer Biother Radiopharmacol 19 (2004) 388-390
43. Dale R. Use of the linear-quadratic radiobiological model for quantifying kidney response in targeted radiotherapy. Cancer Biother Radiopharmacol 19 (2004) 363-370
44. Breitz H., Wendt R., Stabin M., et al. Dosimetry of high dose skeletal targeted radiotherapy (STR) with (166)Ho-DOTMP. Cancer Biother Radiopharmacol 18 (2003) 225-230
45. De Jong M., Valkema R., Jamar F., et al. Somatostatin receptor-targeted radionuclide therapy of tumors: Preclinical and clinical findings. Semin Nucl Med 32 (2002) 133-140
46. Barone R., Borson-Chazot F., Valkema R., et al. Patient-specific dosimetry in predicting renal toxicity with (90)Y-DOTATOC: Relevance of kidney volume and dose rate in finding a dose-effect relationship. J Nucl Med 46 Suppl. 1 (2005) 99S-106S
47. Rajon D.A., Shah A.P., Watchman C.J., et al. A hyerboliod representation of the bone-marrow interface within 3D NMR images of trabecular bone: Applications to skeletal dosimetry. Phys Med Biol 48 (2003) 1721-1740
48. Juweid M.E., Zhang C.H., Blumenthal R.D., et al. Prediction of hematologic toxicity after radioimmunotherapy with (131)I-labeled anticarcinoembryonic antigen monoclonal antibodies. J Nucl Med 40 (1999) 1609-1616
49. Siegel J.A., Yeldell D., Goldenberg D.M., et al. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients. J Nucl Med 44 (2003) 67-76